In drug development, key regulators such as the IL-21 receptor and LMP-1 may be valuable as therapeutic targets for EBV-positive DLBCL, and monoclonal antibodies or small molecule antagonists targeting these regulators may be beneficial for the survival of patients. The gene discussed is IL21R; the disease is diffuse large B-cell lymphoma.